Replacing, reducing and refining the use of animals in tuberculosis vaccine 1 research

Replacing, reducing and refining the use of animals in tuberculosis vaccine 1 research

Tuberculosis (TB) remains a serious global health threat and an improved vaccine is urgently needed. New candidate TB vaccines are tested using preclinical animal models such as mice, guinea pigs, cattle and non-human primates. Animals are routinely infected with virulent Mycobacterium tuberculos...

Descripció completa

Dades bibliogràfiques
Autors principals:	Tanner, R, McShane, H
Format:	Journal article
Publicat:	ALTEX Edition 2016

Ítems similars

Vaccines for tuberculosis
per: McShane, H
Publicat: (2013)

Reducing, refining and replacing the use of animals in toxicity testing /
per: Allen, David G. (David Glenwood), et al.
Publicat: (2014)

Vaccine strategies against tuberculosis
per: H McShane
Publicat: (2009-03-01)

Insights and challenges in tuberculosis vaccine development
per: McShane, H
Publicat: (2019)

Tuberculosis vaccines: beyond bacille Calmette–Guérin
per: McShane, H
Publicat: (2011)

Tuberculosis vaccines: Beyond bacilli Calmette-Guérin
per: McShane, H
Publicat: (2011)

Tuberculosis vaccines: Progress and challenges
per: Checkley, A, et al.
Publicat: (2011)

Improving tuberculosis vaccine trial efficiency: a tough nut to crack
per: McShane, H
Publicat: (2023)

Why don’t we have an effective tuberculosis vaccine yet?
per: Davenne, T, et al.
Publicat: (2016)

Editorial: 3Rs approach (replace, reduce and refine animal models) to improve preclinical research
per: Laura Calvillo
Publicat: (2022-10-01)

Clinical testing of tuberculosis vaccine candidates
per: Hatherill, M, et al.
Publicat: (2016)

The VALIDATE network: accelerating vaccine development for tuberculosis, leishmaniasis, melioidosis and leprosy
per: Vermaak, S, et al.
Publicat: (2023)

A Novel Dental Caries Model Replacing, Refining, and Reducing Animal Sacrifice
per: Amit Wolfoviz-Zilberman, et al.
Publicat: (2021-08-01)

Dual neonate vaccine platform against HIV-1 and M. tuberculosis.
per: Hopkins, R, et al.
Publicat: (2011)

Tuberculosis vaccines in the era of Covid-19 - what is taking us so long?
per: Dockrell, HM, et al.
Publicat: (2022)

Factors influencing the higher incidence of tuberculosis among migrants and ethnic minorities in the UK
per: Hayward, S, et al.
Publicat: (2018)

Human and Bovine Tuberculosis
per: McShane, H
Publicat: (2016)

Mucosal delivery of tuberculosis vaccines: a review of current approaches and challenges
per: Stylianou, E, et al.
Publicat: (2019)

A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data.
per: McShane, H, et al.
Publicat: (2014)

A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data
per: McShane, H, et al.
Publicat: (2014)

Vaccination against tuberculosis: how can we better BCG?
per: Pitt, J, et al.
Publicat: (2013)

Vaccination against tuberculosis: How can we better BCG?
per: Pitt, J, et al.
Publicat: (2013)

Tuberculosis vaccines in the era of Covid-19 – what is taking us so long?
per: Hazel M. Dockrell, et al.
Publicat: (2022-05-01)

Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review
per: Mcshane, H, et al.
Publicat: (2016)

The humoral immune response to BCG vaccination
per: Tanner, R, et al.
Publicat: (2019)

Survey of Canadian animal-based researchers' views on the Three Rs: replacement, reduction and refinement.
per: Nicole Fenwick, et al.
Publicat: (2011-01-01)

Vaccine strategies against tuberculosis.
per: Mcshane, H
Publicat: (2009)

Tuberculosis vaccines in clinical trials.
per: Rowland, R, et al.
Publicat: (2011)

The Sharing Experimental Animal Resources, Coordinating Holdings (SEARCH) Framework: Encouraging Reduction, Replacement, and Refinement in Animal Research.
per: Bethny Morrissey, et al.
Publicat: (2017-01-01)

Controlled human infection models: is it really feasible to give people tuberculosis?
per: McShane, H
Publicat: (2020)

Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants.
per: Ota, M, et al.
Publicat: (2011)

Local pulmonary immunological biomarkers in tuberculosis
per: Morrison, H, et al.
Publicat: (2021)

Developing an improved vaccine against tuberculosis.
per: Mcshane, H
Publicat: (2004)

Tuberculosis vaccines: progress and challenges.
per: Checkley, A, et al.
Publicat: (2011)

Tuberculosis vaccines: present and future.
per: Minassian, A, et al.
Publicat: (2008)

Challenges in developing a controlled human tuberculosis challenge model
per: Jackson, S, et al.
Publicat: (2022)

In vitro mycobacterial growth inhibition assays: A tool for the assessment of protective immunity and evaluation of tuberculosis vaccine efficacy
per: Mcshane, H, et al.
Publicat: (2017)

Refinement of Animal Experiments: Replacing Traumatic Methods of Laboratory Animal Marking with Non-Invasive Alternatives
per: Ilya Klabukov, et al.
Publicat: (2023-11-01)

Tuberculosis vaccine promises sterilizing immunity.
per: Mcshane, H, et al.
Publicat: (2011)

Refinements to Animal Models for Biomedical Research
per: Gabrielle C. Musk
Publicat: (2020-12-01)